Skip to content

To keep going please Log in.

or

By submitting my information, I agree to the Privacy Policy and Terms of Service.

To keep going please Log in.

or

By submitting my information, I agree to the Privacy Policy and Terms of Service.

To keep going please Log in.

or

By submitting my information, I agree to the Privacy Policy and Terms of Service.

To keep going please Log in.

or

By submitting my information, I agree to the Privacy Policy and Terms of Service.

BBIO BridgeBio Pharma, Inc. Common Stock
$81.99 -0.10% -0.08
Notify me if price changes either direction
Interactive Brokers Logotype

Buy BBIO stocks now with Interactive Brokers – the most advanced investment platform

Contents
  • Performance
  • Key stats
  • Financials
  • US politician trades
Loading

Key Stats

Market cap. 16.1B
Enterprise value 17.2B
Trailing PE -21.690475625336
Forward PE 139.77419
PEG Ratio 4.7719046375739
Enterprise to EBITDA -34.522
Enterprise to revenue 29.696
Price to book MRQ -7.0390934885853
Price to sales TTM 27.385408

Financials

Fiscal Year Ends 2025-12-31
Most Recent Quarter (MRQ) 2026-03-31
Revenue (TTM) 580.0M
EBITDA -498881984
Diluted EPS TTM -3.73
Total Cash (MRQ) 940.2M
Current ratio (MRQ) 1.521
Operating Cash Flow (TTM) -443953984

BBIO trades by the US politicians

Percentage
0% 0 sells
100% 0 buys
Amount
$0 0 sells
$0 0 buys
In the last 0 months

Recent BBIO News

Home

IMPORTANT NOTICE

Finbold is a news and information website. This Site may contain sponsored content, advertisements, and third-party materials, for which Finbold expressly disclaims any liability.

RISK WARNING: Cryptocurrencies are high-risk investments and you should not expect to be protected if something goes wrong. Don’t invest unless you’re prepared to lose all the money you invest. (Click here to learn more about cryptocurrency risks.)

By accessing this Site, you acknowledge that you understand these risks and that Finbold bears no responsibility for any losses, damages, or consequences resulting from your use of the Site or reliance on its content. Click here to learn more.